Protalix BioTherapeutics announced a net income of $4 million for Q3 2026, up from $2.4 million in Q3 2025, with total revenues rising to $75.6 million year-to-date. The company expects to meet or exceed its 2026 revenue guidance of $78-83 million, supported by sales of its therapies Elfabrio and Elelyso. Protalix is progressing its PRX-115 Phase 2 study for uncontrolled gout, aiming to address a significant unmet medical need, with top-line results expected in late 2027. The company ended Q3 with $48.5 million in cash and short-term deposits, positioning it well for continued R&D and commercial activities.
Protalix BioTherapeutics financial results provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 10, 2026 17:51 WIB: 76 of 150 health-sector US stocks rose, 58 fell. Notable movers include Revvity Inc at USD 163.35 with 1.64% gain and 100% sell order activity, LifeStance Health Group Inc at USD 14.81 with 1.44% gain, and Moderna, Inc. at USD 272.82 with 1.42% gain and balanced buy/sell orders.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
